EAM Investors LLC bought a new position in Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 42,662 shares of the company’s stock, valued at approximately $578,000. EAM Investors LLC owned approximately 0.34% of Spring Bank Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sphera Funds Management LTD. acquired a new position in shares of Spring Bank Pharmaceuticals in the 2nd quarter worth approximately $2,370,000. AXA acquired a new position in shares of Spring Bank Pharmaceuticals in the 2nd quarter worth approximately $2,894,000. Parsons Capital Management Inc. RI grew its position in shares of Spring Bank Pharmaceuticals by 19.6% in the 1st quarter. Parsons Capital Management Inc. RI now owns 233,443 shares of the company’s stock worth $2,078,000 after acquiring an additional 38,278 shares in the last quarter. Private Capital Advisors Inc. grew its position in shares of Spring Bank Pharmaceuticals by 50.0% in the 2nd quarter. Private Capital Advisors Inc. now owns 56,250 shares of the company’s stock worth $762,000 after acquiring an additional 18,750 shares in the last quarter. Finally, Morse Asset Management Inc grew its position in shares of Spring Bank Pharmaceuticals by 156.9% in the 2nd quarter. Morse Asset Management Inc now owns 63,700 shares of the company’s stock worth $862,000 after acquiring an additional 38,900 shares in the last quarter. Institutional investors own 28.26% of the company’s stock.

Several research analysts have recently commented on SBPH shares. Cantor Fitzgerald started coverage on Spring Bank Pharmaceuticals in a research report on Wednesday, July 19th. They issued an “overweight” rating and a $29.00 target price for the company. ValuEngine upgraded Spring Bank Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 6th. Chardan Capital decreased their target price on Spring Bank Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday, August 1st. Finally, Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $26.33.

In other news, Director David Arkowitz purchased 2,500 shares of the stock in a transaction that occurred on Friday, August 4th. The shares were purchased at an average cost of $12.24 per share, for a total transaction of $30,600.00. Following the completion of the purchase, the director now directly owns 17,086 shares of the company’s stock, valued at approximately $209,132.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have purchased 5,500 shares of company stock worth $70,160 over the last 90 days. Corporate insiders own 17.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.watchlistnews.com/eam-investors-llc-takes-578000-position-in-spring-bank-pharmaceuticals-inc-sbph/1598616.html.

Spring Bank Pharmaceuticals, Inc. (SBPH) opened at 16.84 on Friday. The stock has a 50 day moving average price of $14.77 and a 200 day moving average price of $14.77. Spring Bank Pharmaceuticals, Inc. has a 12 month low of $6.31 and a 12 month high of $16.84. The firm’s market cap is $213.82 million.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Institutional Ownership by Quarter for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.